Antitumor Effect of Ruthenium(II) with 2-Mercaptothiazoline Ligand Complex in Murine Melanoma Model
ACS Omega · 18.08.2026 · 11 (32) · 47570-47578
DOI: 10.1021/acsomega.6c01894 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 04.08.2026. Verfasst von Gabriela Fernandes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Universidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo 14404-600, Brazil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funda??o de Amparo ? i Pesquisa do Estado de S?o Paulo, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico.
Abstract (Originalsprache)
Ruthenium-based complexes have been explored as promising alternatives in antineoplastic therapy due to their enhanced selectivity for cancer cells. In this context, the present study evaluated the antitumor potential of the ruthenium complex [Ru(mtz)(dppe)2]PF6, named RuMTZ, in C57BL/6 mice bearing B16-melanoma, as well as its toxicity. In addition to tumor weight and mitotic frequency, cleaved caspase-3, γH2AX, and MAPK/ERK expression levels were analyzed by immunohistochemistry. The toxicity of the treatments was assessed through alterations in body and organ weight, biochemical parameters of liver and kidney function, and genotoxicity in bone marrow cells. RuMTZ led to a significant reduction in mitotic frequency and tumor weight, with a tumor growth inhibition rate equivalent to 94.9%. The antimelanoma activity of RuMTZ was accompanied by increased levels of cleaved caspase-3, γH2AX, and MAPK/ERK. These data indicate that RuMTZ induced DNA strand breaks, which may be, at least in part, related to the induction of caspase- and ERK1/2-mediated apoptosis. RuMTZ treatment, unlike cisplatin, showed no weight loss or impairment of liver and kidney functions. However, similar to other metallopharmaceuticals, it caused myelosuppression, evidenced by the absence of erythrocytes. These findings support the promising antitumor activity of RuMTZ, indicating its potential as a metallodrug.
Autor:innen und Institutionen
- Universidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo 14404-600, Brazil.
- Universidade Federal de São Carlos, Departamento de Química, Rodovia Washington Luis s/n Km 235, São Carlos, São Paulo 13565-905, Brazil.
- Georgetown University, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, District of Columbia 20057, United States.
ORCID-Profile: Gabriela Fernandes, Arthur Barcelos Ribeiro, Monize Martins da Silva, D C Tavares
Förderung
- Funda??o de Amparo ? i Pesquisa do Estado de S?o Paulo
- Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
Zitieren
APA
Fernandes, G., Ribeiro, A. B., de Melo, M. R. S., Squarisi, I. S., da Silva, L. H. D., da Silva, M. M., de Assis, S., Batista, A. A., & Tavares, D. C. (2026). Antitumor Effect of Ruthenium(II) with 2-Mercaptothiazoline Ligand Complex in Murine Melanoma Model. ACS Omega, 11(32), 47570-47578. https://doi.org/10.1021/acsomega.6c01894
Vancouver
Fernandes G, Ribeiro AB, de Melo MRS, Squarisi IS, da Silva LHD, da Silva MM, et al. Antitumor Effect of Ruthenium(II) with 2-Mercaptothiazoline Ligand Complex in Murine Melanoma Model. ACS Omega. 2026;11(32):47570-47578. doi:10.1021/acsomega.6c01894
BibTeX
@article{Fernandes2026,
author = {Fernandes, Gabriela and Ribeiro, Arthur Barcelos and de Melo, Matheus Reis Santos and Squarisi, Iara Silva and da Silva, L H D and da Silva, Monize Martins and de Assis, Sonia and Batista, Alzir Azevedo and Tavares, D C},
title = {Antitumor Effect of Ruthenium(II) with 2-Mercaptothiazoline Ligand Complex in Murine Melanoma Model},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {32},
pages = {47570--47578},
doi = {10.1021/acsomega.6c01894}
}
EUVIMED